A previous study showed that immune inhibitory anti-CTLA4 (Ipilimumab) treatment could increase IFNγ production by T cells—and IFNγ-related gene deficiency in tumor cells induced resistance to anti-CTLA4 immune checkpoint therapy29. This evidence concerns the gene CTLA4 and neoplasm.